Neurol. praxi. 2020;21(6):448-452 | DOI: 10.36290/neu.2020.098

Negative prognostic factors in multiple sclerosis

MUDr. Jiří Piťha
MS centrum při Neurologickém oddělení KZ, a. s. - Nemocnice Teplice, o. z., Teplice

Multiple sclerosis is a heterogeneous disease with a variable prognosis. The choice of optimal treatment in the initial stages of the disease fundamentally affects its further course. It is an effort to find the most ideal prognostic factors that would differentiate patients at risk of higher clinical activity and progression of disability with the need to introduce more vigorous treatment. These indicators include demographic and clinical factors, magnetic resonance imaging findings, some laboratory biomarkers, and environmental factors. More information is provided by a comprehensive assessment of the forecast based on multivariate prediction models. Although a recent systematic review states that most of these prognostic factors are at high risk of bias and lacking external validation and impact analysis, this does not diminish their importance in clinical practice.

Keywords: multiple sclerosis, poor prognosis, magnetic resonance imaging, biomarkers.

Received: August 24, 2020; Revised: September 8, 2020; Accepted: September 8, 2020; Prepublished online: September 8, 2020; Published: January 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J. Negative prognostic factors in multiple sclerosis. Neurol. praxi. 2020;21(6):448-452. doi: 10.36290/neu.2020.098.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168(2): 96-106. Go to original source... Go to PubMed...
    2. Comi G, Radaelli M, Soelberg Sørensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 2017; 1;389: 1347-1356. Go to original source... Go to PubMed...
    3. Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol 2008; 65(11): 1449-1453. Go to original source... Go to PubMed...
    4. Bertolotto A. Evaluation of the impact of neutralizing antibodies on IFNβ response. Clin Chim Acta 2015; 449: 31-36. Go to original source... Go to PubMed...
    5. Bittner S, Steffen F, Uphaus T, Muthuraman M, Fleischer V, Salmen A, Luessi F, Berthele A, Klotz L, Meuth SG, Bayas A, Paul F, Hartung HP, Linker R, Heesen C, Stangel M, Wildemann B, Then Bergh F, Tackenberg B, Kuempfel T, Weber F, Zettl UK, Ziemann U, Tumani H, Groppa S, Mühlau M, Lukas C, Hemmer B, Wiendl H, Gold R, Zipp F; KKNMS consortium.Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine 2020; 56: 102807. Go to original source... Go to PubMed...
    6. Brown FS, Glasmacher SA, Kearns PKA, MacDougall N, Hunt D, Connick P, Chandran S. Systematic review of prediction models in relapsing remitting multiple sclerosis. PLoS One 2020; 26; 15(5): e0233575. Go to original source... Go to PubMed...
    7. Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Barkhof F, Uitdehaag BMJ, Schoonheim MM, Geurts JJG. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain 2018; 141(9): 2605-2618. Go to original source... Go to PubMed...
    8. Elliott C, Belachew S, J Wolinsky J, Hauser SL, Ludwig Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain 2019; 142(9): 2787-2799. Go to original source... Go to PubMed...
    9. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, Thompson AJ, Miller. DH Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131(3): 808-17. Go to original source... Go to PubMed...
    10. Guillemin, F, Baumann C, Epstein J, Kerschen P, Garot T, Mathey G, Debouverie M, LORSEP Group. Older age at multiple sclerosisonset is an independent factor of poor prognosis: a population-based cohort study. Neuroepidemiology 2017; 48: 179-187. Go to original source... Go to PubMed...
    11. Havas J, Leray E, Rollot F, Casey R, Michel L, Lejeune F, Wiertlewski S, Laplaud D, Foucher Y. Predictive medicine in multiple sclerosis: A systematic review. Mult Scler Relat Disord 2020; 40: 101928. Go to original source... Go to PubMed...
    12. Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Seidl Z, Vaneckova M, Zivadinov R. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: A 5-year longitudinal study. J Neurol Sci 2009; 282: 112-119. Go to original source... Go to PubMed...
    13. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HK, Gasperini C, Filippi M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999; 353(9157): 964-969. Go to original source... Go to PubMed...
    14. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9(5): 520-532. Go to original source... Go to PubMed...
    15. Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006; 63(12): 1686-1691. Go to original source... Go to PubMed...
    16. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol 2014; 72(Suppl. 1): 1-5. Go to original source... Go to PubMed...
    17. Lukas C, Minneboo A, de Groot V, Moraal B, Knol DL, Polman Ch. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81(12): 1351-1356. Go to original source... Go to PubMed...
    18. Manouchehrinia A, Hedström AK, Alfredsson L, Olsson T, Hillert J, Ramanujam R. Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis. Front Neurol 2018; 11(9): 232. Go to original source... Go to PubMed...
    19. Marrie RA. Comorbidity in multiple sclerosis: Past, present and future. Clin Invest Med 2019; 42(1): E5-E12. Go to original source... Go to PubMed...
    20. Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol 2016; 15(6): 574-584. Go to original source... Go to PubMed...
    21. McDonald WI, Compston A, Edan G, Goodkin D, Hartung H P, Lublin F D, McFarland H F, Paty D W, Polman C H, Reingold SC, Sandberg-Wollheim M, Sibley W, A Thompson, van den Noort S, Weinshenker B Y, Wolinsky J S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121-127. Go to original source... Go to PubMed...
    22. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65(6): 727-732. Go to original source... Go to PubMed...
    23. Perini P, Ranzato F, Calabrese M, Battistin L, Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77(8): 953-955. Go to original source... Go to PubMed...
    24. Ramanujam R, Hedström AK, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, Hillert J. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 2015; 72(10): 1117-1123. Go to original source... Go to PubMed...
    25. Rio J, Castil lo J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X. Measures in the first year of therapy predict the response to inter-feron beta in MS. Mult Scler 2009; 15(7): 848-853. Go to original source... Go to PubMed...
    26. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol 2019; 15(5): 287-300. Go to original source... Go to PubMed...
    27. Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. Brain 2017; 140(11): 2814-2819. Go to original source... Go to PubMed...
    28. Scalfari, A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long - term disability. Brain 2010; 133: 1914-1929. Go to original source... Go to PubMed...
    29. Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68(2): 193-203. Go to original source... Go to PubMed...
    30. Stellmann JP, Neuhaus A, Lederer Ch, Daumer M, Heesen Ch. Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review. PLoS One 2014; 9(3): e92761. Go to original source... Go to PubMed...
    31. Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015; 138(7): 1863-1874. Go to original source... Go to PubMed...
    32. Toledo J, Sepulcre J, Salinas-Alaman A, García-Layana A, Murie-Fernandez M, Bejarano B, Villoslada P. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 2008; 14(7): 906-912. Go to original source... Go to PubMed...
    33. Trojano M, Avolio C, Manzari C, Calò A, De Robertis F, Serio G, Livrea P. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58(3): 300-306. Go to original source... Go to PubMed...
    34. Ventura RE, Antezana AO, Bacon T, Kister I. Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. Mult. Scler 2017; 23: 1554-1557. Go to original source... Go to PubMed...
    35. Villar LM, Masjuan J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, Bootello A, Alvarez-Cermeño JC. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53(2): 222-226. Go to original source... Go to PubMed...
    36. Ziemssen T, Akgün K, Brück W. Molecular biomarkers in multiple sclerosis. J Neuroinflammation 2019; 16: 272. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.